A few randomized medical studies (RCTs) have recently tested adjuvant chemotherapy to risky prostate cancer patients (PCA) after main regional treatment. The purpose of the study was to perform an organized review and meta-analysis of RCTs evaluating the adjuvant chemotherapy in high-risk prostate cancer tumors clients after primary regional treatment. The main endpoint was general success (OS). The secondary endpoint had been disease-free success (DFS) and biochemical recurrence-free survival (BRFS). an organized article on PubMed/Medline, Embase, and Cochrane databases had been carried out to identify appropriate studies posted in English up to March 2020. Six trials had been selected for addition. There were 7 studies contained in the present research. The meta-analysis failed to show a substantial OS reap the benefits of adjuvant chemotherapy in customers with high-risk prostate disease after primary local treatment (risk ratio [HR] 0.87; 95% confidence period [CI], 0.72-1.05; p = 0.15). But docetaxel in customers with high-risk prostate cancer after main neighborhood therapy was connected with a slightly OS improvement (hour 0.79; 95% CI, 0.63-0.98; p = 0.03). In addition it failed to show an important advantage in DFS and BRFS in clients with high-risk prostate cancer (HR 0.89, 95% CI, 0.75-1.06, p = 0.18; HR 0.85, 95% CI, 0.69-1.06, p = 0.16). This meta-analysis reveals a slightly OS benefit from docetaxel in customers with high-risk prostate cancer after major neighborhood therapy. It would not show a significant advantage in DFS and BRFS from adjuvant chemotherapy in patients with risky prostate cancer tumors.This meta-analysis shows a slightly OS benefit from docetaxel in customers with high-risk prostate disease after main neighborhood therapy. It did not show a substantial benefit in DFS and BRFS from adjuvant chemotherapy in patients with high-risk prostate cancer tumors. Curcumin is an encouraging drug applicant, but its usage for dermal application is limited due to its poor aqueous solubility. Hence, formulations that raise the solubility of curcumin are essential to fully take advantage of the healing potential of curcumin. Various earlier scientific studies address this problem, but an evaluation of this efficacy between these formulations stays hard. The cause of this is a missing standard formulation as benchmark control and an easy-to-use skin penetration design check details that enables for a quick discrimination between various formulations. Outcomes reveal that the used skin penetration design is a suitable and functional device that permits not only a fast dedication associated with the dermal penetration effectiveness of curcumin from various formulations but in addition an in depth and mechanistic home elevators the fate of chemical substances after dermal penetration. Ethanolic solutions containing 0.25% curcumin were found to be the best option standard formulation. “Three-port” laparoscopic radical prostatectomy (LRP) is used as a replacement for the Bioavailable concentration old-fashioned 4- to 5-port LRP to treat prostate cancer tumors (PCa) patients within our organization. To judge the educational curve of an innovative “3-port” LRP for PCa clients. 206 customers whom received “3-port” LRP had been retrospectively evaluated between January 2016 and December 2019 at our organization. According to the various many years of businesses done, all of the customers had been split into group A (No. 1-50), group B (No. 51-107), group C (No. 108-160), and team D (No. 161-206). A learning curve had been portrayed by examining the variables of operative time (OT), determined bloodstream loss (EBL), hospitalization, and drainage indwelling times. All teams were similar with regard to the preoperative attributes (p > 0.05). The sloping learning curve when it comes to surgeon indicated that OT and EBL were highly correlated with an accumulated knowledge when compared between team A